Roche Holding AG isn’t done making moves in the obesity market after last month’s agreement to buy Carmot Therapeutics Inc. for as much as $3.1 billion (CHF2.64 billion).
This content was published on
2 minutes
Bloomberg
The Swiss drugmaker said on Tuesday that it’s on the hunt for additional biotech partners to help it challenge weight-loss leaders Novo Nordisk A/S and Eli Lilly & Co. Roche is looking for new ways of adjusting metabolism that could ultimately be combined with treatments it’s gaining in the Carmot deal.
“This is opening up a whole new vista for us,” James Sabry, Roche’s head of partnering, said in an interview on the sidelines of the JPMorgan Healthcare Conference in San Francisco.
More
More
Roche declares war on obesity with billion-dollar takeover
This content was published on
Pharmaceutical company Roche is entering the fight against obesity with the $2.7 billion takeover of United States firm Carmot Therapeutics.
Carmot was one in a flurry of recent deals Roche has made to bolster its pipeline. The company is also interested in oncology, neurology and ophthalmology as well as cardiovascular medicine, Sabry said.
While many companies are trying to break into the hot weight-loss market, Sabry said Roche is one of only a handful of suitors with the size and global reach to run the large, costly trials necessary to bring new drugs to market. Marketing obesity medicines is also more complicated than other areas like cancer because drugmakers need to deal with primary-care doctors instead of a few specialised treatment centres, he said.
More
More
What lies ahead for Switzerland: the economic outlook for 2024
This content was published on
SWI swissinfo.ch journalists select the major developments that await the Swiss economy in 2024.
“When we’re trying to get a deal done, we find more competitors in oncology,” he said. “You’d think everyone must be competing with you for metabolism drugs, but it’s not that way.”
Roche was one of the first pharmaceutical companies to work on an experimental drug in the GLP-1 class, a category that includes Novo’s Wegovy and Lilly’s Zepbound. But it halted development more than a decade ago after patients dropped out of a study due to side effects such as nausea.
Two decades after tsunami, Swiss tourists flock to Southeast Asia
This content was published on
Twenty years after a catastrophic tsunami in Southeast Asia, the region is again a top destination for Swiss, including at Christmas.
Swiss forests better equipped for storms 25 years after Lothar
This content was published on
Twenty-five years after Hurricane Lothar wreaked havoc in Switzerland, the country’s forests are now better prepared, experts say.
Media: Swiss medical services done abroad are billed at Swiss rates
This content was published on
In Switzerland, some medical services carried out abroad are still billed at Swiss rates, despite costing less, RTS reports.
This content was published on
Sophie Hediger, a member of the Swiss national snowboard cross team, has died in an avalanche in Arosa. She was 26 years old.
This content was published on
Several Swiss films exceeded the 100,000 admissions mark worldwide in 2024 and received widespread praise at international film festivals.
Swiss Alpine resorts covered in white gold for Christmas
This content was published on
Many areas at low altitudes in Switzerland are enjoying a blanket of snow. In the mountains, intense precipitation has delighted skiers.
SWISS makes emergency landing in Austria after smoke in cockpit
This content was published on
Swiss International Airlines (SWISS) made an emergency landing of an Airbus in Graz, Austria on Monday evening after engine problems.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.